Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
In order to study alternatives at the tissue biopsy to study EGFR status in NSCLC patients, we evaluated three different liquid biopsy platforms (plasma, urine and exhaled breath condensate, EBC). We also reviewed the literature of the cfDNA biological sources other than plasma and compared our resu...
Enregistré dans:
Auteurs principaux: | Michela Verzè, Roberta Minari, Letizia Gnetti, Paola Bordi, Alessandro Leonetti, Agnese Cosenza, Leonarda Ferri, Maria Majori, Massimo De Filippo, Sebastiano Buti, Donatello Gasparro, Rita Nizzoli, Cinzia Azzoni, Lorena Bottarelli, Anna Squadrilli, Paola Mozzoni, Marcello Tiseo |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/baf6dfbf7bf446ec935f7672e54ef210 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer
par: Kazutaka Fujita, et autres
Publié: (2021) -
Fragmentomic cfDNA Patterns in Noninvasive Prenatal Testing and Beyond
par: Kavish Kohabir, et autres
Publié: (2021) -
Validating quantitative PCR assays for cfDNA detection without DNA extraction in exercising SLE patients
par: Elmo W. I. Neuberger, et autres
Publié: (2021) -
Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients
par: Xiaorong Zhou, et autres
Publié: (2021) -
Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer
par: Keita Tanaka, et autres
Publié: (2021)